Stay updated on Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The record describes a Phase I/II study of Poly-ICLC combined with anti-PD-1 or anti-PD-L1 therapies for advanced solid cancers. It is marked terminated, with an actual enrollment of 7 participants.
    Difference
    49%
    Check dated 2026-11-08T14:24:01.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer’s revision identifier changes from v3.7.2 to v3.8.0, while the page still displays a 403 Forbidden error rather than study details.
    Difference
    0.2%
    Check dated 2026-11-01T15:45:32.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page no longer displays the 403 error screen and instead shows an NIH-wide announcement. The study record content remains absent.
    Difference
    2%
    Check dated 2026-10-25T15:36:25.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-18T22:11:58.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T21:50:13.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The study record page no longer shows the 403 Forbidden error content, removing the previously displayed error state.
    Difference
    0.5%
    Check dated 2026-09-27T22:09:26.000Z thumbnail image

Stay in the know with updates to Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page.